Sign In

Michael Martin

Plexium

Michael Martin, Ph.D. - President and CEO of Plexium

Michael Martin, Ph.D. is the President and Chief Executive Officer of Plexium, a leading next-generation targeted protein degradation (TPD) company.134 He joined Plexium in January 2024 following his 12-year tenure at Takeda Pharmaceuticals, where he most recently served as the Global Head of the Center for External Innovation.12

At Plexium, Dr. Martin is responsible for advancing the company's clinical-stage pipeline and progressing more TPD programs against important cancer targets into the clinic.1 He is excited to lead Plexium in developing transformative therapies for difficult to treat cancers and other diseases.1

Prior to joining Takeda in 2012, Dr. Martin held executive and scientific roles at various biotech companies, including Intellikine Inc. (acquired by Takeda), TargeGen, Inc. (acquired by Sanofi-Aventis), Arena Pharmaceuticals, Inc. (acquired by Pfizer) and Monsanto Corporation (acquired by Bayer).1

Dr. Martin holds a Ph.D. in Medicinal Chemistry from the University of Illinois, a M.S. in Analytical Chemistry, and B.S. degrees in Chemistry and Mathematics.1 He has extensive experience as a corporate board member for both private and publicly traded companies and has acted as an advisor to several notable biotech investment funds in the United States, Europe, and Japan.1

Highlights

Jan 16 · linkedin

Today, I am honored to begin my new role as President and CEO of Plexium, where we have a bold vision to create the next-generation of targeted protein degradation (TPD) therapies for patients in need. I have been impressed by the robust science, talented team, board, and investors who share a commitment to execute on our mission. With our lead program PLX-4545 in Phase 1, and an emerging pipeline of transformative therapeutics, I believe that the future is bright at Plexium. I look forward to leading the Company through its next phase of growth, as we advance and expand our pipeline of TPD therapies.

Related Questions

What are Michael Martin's key achievements at Takeda Pharmaceuticals?
How does Plexium's approach to targeted protein degradation differ from other companies?
What is the significance of PLX-4545 entering Phase 1 clinical trials?
What are the main diseases Plexium is targeting with their therapies?
How does Michael Martin's background in medicinal chemistry influence his leadership at Plexium?
Michael Martin
Michael Martin, photo 1
Michael Martin, photo 2
Add to my network

Location

San Diego, California, United States